

1 **The stem loop 2 motif is a site of vulnerability for SARS-CoV-2**

2
3 (Valeria Lulla^{1,**}, Michal P. Wandel², Katarzyna J. Bandyra³, Rachel Ulferts⁴, Mary Wu⁴,
4 Tom Dendooven³, Xiaofei Yang⁵)*, Nicole Doyle⁶, Stephanie Oerum⁷, Rupert Beale⁴, Sara M.
5 O'Rourke⁸, Felix Randow², Helena J. Maier⁶, [William Scott⁸, Yiliang Ding⁵, Andrew E.
6 Firth¹, Kotryna Bloznelyte³, Ben F. Luisi³]**

7
8 *These joint-first authors made complementary and equivalent contributions

9 **To whom correspondence may be addressed

10
11 ¹Department of Pathology, Division of Virology, University of Cambridge, Lab Block Level
12 5, Addenbrookes Hospital, Hills Road, Cambridge CB2 0QQ, U.K.

13
14 ²MRC Laboratory of Molecular Biology, Francis Crick Avenue, Cambridge, CB2 0QH, U.K.

15
16 ³Department of Biochemistry, University of Cambridge, Tennis Court Road, Cambridge CB2
17 1GA, U.K.

18
19 ⁴The Francis Crick Institute, 1 Midland Road, London, NW1 1AT, U.K.

20
21 ⁵Department of Cell and Developmental Biology, John Innes Centre, Norwich Research Park,
22 Norwich, NR4 7UH, U.K.

23
24 ⁶Pirbright Institute, Ash Road, Pirbright, Woking, GU24 0NF, U.K.

25
26 ⁷CNRS-Université Paris Diderot, Institut de Biologie Physico-Chimique, 13 rue Pierre et Marie
27 Curie, 75005 Paris, France

28
29 ⁸University of California at Santa Cruz, Santa Cruz California, 95064, U.S.A.

30
31 **Summary:**

32
33 RNA structural elements occur in numerous single stranded (+)-sense RNA viruses. The stem-
34 loop 2 motif (s2m) is one such element with an unusually high degree of sequence
35 conservation, being found in the 3' UTR in the genomes of many astroviruses, some
36 picornaviruses and noroviruses, and a variety of coronaviruses, including SARS-CoV and
37 SARS-CoV-2. The evolutionary conservation and its occurrence in all viral subgenomic
38 transcripts implicates a key role of s2m in the viral infection cycle. Our findings indicate that
39 the element, while stably folded, can nonetheless be invaded and remodelled spontaneously by
40 antisense oligonucleotides (ASOs) that initiate pairing in exposed loops and trigger efficient
41 sequence-specific RNA cleavage in reporter assays. ASOs also act to inhibit replication in an
42 astrovirus replicon model system in a sequence-specific, dose-dependent manner and inhibit
43 SARS-CoV-2 infection in cell culture. Our results thus permit us to suggest that the s2m
44 element is a site of vulnerability readily targeted by ASOs, which show promise as anti-viral
45 agents.

46
47 **Keywords:** s2m, positive-sense RNA virus, coronavirus, astrovirus, gapmer, LNA, therapeutic
48 oligonucleotides, SARS-CoV-2

49 INTRODUCTION

50

51 SARS-CoV-2 is a highly infectious virus and the causative agent of the ongoing COVID-19
52 pandemic. Given the continued rise in cases worldwide, the significant mortality rate and the
53 challenges in predicting the severity of illness in infected individuals (Messner et al., 2020),
54 there is a pressing need for efficacious antiviral therapies (Koirala et al., 2020; Krammer, 2020;
55 [https://www.who.int/emergencies/diseases/ /novel-coronavirus-2019](https://www.who.int/emergencies/diseases/novel-coronavirus-2019)). Moreover, the potential
56 for further outbreaks of infections by emerging pathogenic coronaviruses (Menachery et al,
57 2015; Akula and McCubrey, 2020) places importance on improving fundamental
58 understanding of coronavirus biology, as well as exploring novel therapeutics to build
59 capability for a rapid response to the next zoonotic jump.

60

61 Like other positive-sense (+) single-stranded (ss) RNA viruses, replication of SARS-CoV-2 is
62 orchestrated by virus-encoded enzymes inside infected host cells. The 30 kb long SARS-CoV-
63 2 genomic RNA and the subgenomic mRNA transcripts all contain a common 5'-leader
64 sequence and a common 3' UTR, which harbour several conserved structural elements,
65 including the stem-loop 2 motif (s2m) (Fig. 1A and B) (Rangan et al., 2020; Kim et al., 2020).
66 The s2m, originally identified in astroviruses (Jonassen et al., 1998), is a highly conserved
67 RNA sequence element, present within the 3' UTR in the genomes of many astroviruses, some
68 picornaviruses and noroviruses, and a variety of coronaviruses, including members of the
69 subgenus *Sarbecovirus*, which includes SARS-CoV and SARS-CoV-2 viruses (Tengs et al.,
70 2013, Tengs et al., 2016), and *Merbecovirus*, which includes MERS (Frey et al, 2014), the
71 causative agents of three recent severe human pathogenic outbreaks. The SARS-CoV and
72 SARS-CoV-2 s2m sequences are nearly identical, with only 2 point nucleotide divergence
73 (Fig. 1A), in contrast to the overall 20 % genome-wide sequence difference (Kim et al., 2020).
74 The s2m sequence is also highly conserved in the clinical isolates from patients that have tested
75 positive for SARS-CoV-2 during the current pandemic, although with a few isolated exceptions
76 (GSAID database <https://www.gisaid.org>; UCSC genome browser; Vahed et al.,2020; Yeh and
77 Contreras, 2020). The high degree of s2m sequence conservation is likely to be a direct
78 consequence of a requirement to sustain an elaborate and conserved three-dimensional
79 structure. Indeed, an earlier study of the SARS-CoV s2m element revealed a stable stem loop
80 with a few exposed bases (Fig. 1B) in a 2.7 Å resolution crystal structure (Robertson et al.,
81 2005). Several more recent studies probed RNA accessibility and mapped RNA-RNA
82 interactions of the (+) sense SARS-CoV-2 viral species inside the host cell, confirming that the
83 s2m stem-loop structure folds *in vivo* as well (Huston, 2020; Ziv et al., 2020).

84

85 Because of the apparent high degree of selective pressure to maintain this specific sequence
86 and its structure, the s2m is a promising target for potential antiviral agents, with reduced
87 likelihood of evolving mutations that would lead to resistance. Any agents targeting the s2m
88 element would also have the advantage of acting against a large number of virus RNA species,
89 due to the presence of the element in all (+)-sense virus RNAs, including both the full-length
90 genome and the subgenomic mRNAs. In order to test the accessibility of the s2m element to
91 potential nucleic acid-based therapeutics, we designed a panel of antisense oligonucleotides
92 (ASOs). These oligonucleotides have proven therapeutic potential against viruses and have
93 been undergoing active development for more than a decade (Bennett, 2019). Third-generation
94 ASOs include locked nucleic acids (LNAs), in which a bicyclic linkage at the furanose
95 constrains the conformational freedom of the nucleotide (Singh et al., 1998). LNAs provide
96 high affinity base-pairing to complementary RNA and DNA targets, as well as resistance to
97 nuclease attack (Hagedorn et al., 2018). A version of LNA ASOs known as 'gapmers' consists
98 of LNA bases flanking a central DNA sequence (Wahlenstedt et al, 2000). In this design, LNA

99 bases confer resistance to nucleases and provide high-affinity base-pairing to target RNA,
100 while the central DNA region, once base-paired to RNA, recruits ribonuclease H (RNase H),
101 which acts to cleave the RNA in the RNA-DNA duplex. In this process, the DNA is not
102 digested and thus the gapmer remains intact and free to bind further RNA molecules. Gapmers
103 have already been successfully used in clinical trials to silence target transcripts (Bonneau et
104 al., 2019).

105

106 In this report, we describe the design and testing of several LNA ASOs (gapmers) against the
107 highly conserved structured s2m element from the 3' UTR of SARS-CoV-2. We found by
108 chemical probing of the RNA target element that despite the high degree of structural
109 compactness, ASOs were successfully disrupting the s2m structure. Furthermore, gapmers
110 were capable of inducing sequence-specific RNA cleavage *in vitro* and in multiple independent
111 cell-based platforms, including a human reporter system, an astrovirus replicon assay, and
112 direct inhibition of SARS-CoV-2 replication in infected cells. Our results support targeting of
113 the s2m element and other conserved structures with predicted exposed loops in the viral
114 genomes by ASOs. In addition, the particular gapmer designs described here may offer suitable
115 lead compounds for further development as antiviral therapeutics to treat COVID-19 and other
116 diseases caused by RNA viruses possessing the s2m element in their genomes.

117

118 RESULTS

119

120 Model for the s2m element in the context of the SARS-CoV-2 3' UTR

121

122 Given the high sequence similarity between the s2m elements in the SARS-CoV-2 and SARS-
123 CoV genomes (Fig. 1A), the corresponding structures are expected to show high similarity as
124 well. The crystal structure of the SARS-CoV s2m reveals a stem loop with a small pocket that
125 can accommodate cations (Fig. 1B; Robertson et al., 2005) and suggests a similar fold for the
126 SARS-CoV-2 s2m. To test this experimentally, we probed the structure of the SARS-CoV-2
127 s2m element within the genomic 3' UTR using SHAPE (Selective 2'-Hydroxyl Acylation
128 analyzed by Primers Extension) (Spitale et al., 2013). The SHAPE reactivity profile strongly
129 agrees with the crystal structure of the SARS-CoV s2m element (Fig. 1C). For instance, high
130 SHAPE reactivities were found at the loop region (G71-A75), indicating strong possibility of
131 a single-stranded nature, while low SHAPE reactivities were found for nucleotides predicted
132 to be base-paired, such as nucleotides 54-58, and nucleotides 90-94. We performed further
133 SHAPE probing on an extended version of the 3' UTR RNA ("extended 3' UTR") that
134 additionally includes ORF10 and the region immediately upstream from it (ORF10 may not be
135 protein coding; Taiaroa et al., 2020; Jungreis et al., 2020) (Fig. S1 and Table 1). We found a
136 high degree of consistency between the SHAPE profiles for the s2m element in the extended
137 and non-extended constructs (Pearson correlation coefficient PCC = 0.996, Fig. S1B and S1C),
138 indicating that the s2m element in the 3' UTR is stably folded and is unlikely to be affected by
139 flanking regions such as ORF10. Stable structural unit formation by s2m, maintained within
140 an extended surrounding sequence, has also been observed in a recent NMR and DMS chemical
141 probing study (Wacker et al., 2020), with experimental data agreeing with the s2m secondary
142 structure proposed here (Fig. 1C). Further support for our findings comes from recent whole-
143 genome studies of the SARS-CoV-2 RNA structure, which show good agreement between
144 SHAPE reactivity and *in silico* predictions and identify s2m stem loop in this context (Huston,
145 2020; Manfredonia et al., 2020).

146

147 To further investigate potential structures formed by the viral 3' UTR as a whole, we used cryo-
148 electron microscopy. Imaging this RNA fragment mainly yielded elongated shapes resembling

149 thick rope, up to 500 Å in length (Fig. 1D). A subset of the ropey particles were less extended,
150 measuring around 300 Å, which is about half the length expected for an elongated polymer,
151 implying that the RNA there is semi-compact. These particles were subjected to computational
152 2D/3D averaging in an attempt to reveal underlying shared structural features (Fig 1E and F).
153 However, none could be clearly identified, suggesting that the 3' UTR RNA does not fold into
154 a well-defined structure, at least *in vitro*.

155

156 Our cryo-electron microscopy observations give support to earlier *in vivo* studies, where cells
157 infected with SARS-CoV-2 virus were probed by cryo-electron tomography (Klein et al.,
158 2020). Both the tomography study and our single-particle imaging reveal small, high-contrast
159 features at the periphery of the RNA particles, which might represent views down the long axis
160 of some duplex RNA regions (Fig. 1D, red arrows).

161

162 Overall, based on the prediction from the SARS-CoV s2m RNA crystal structure and our
163 SHAPE probing results, we conclude that the s2m element in the 3' UTR of SARS-CoV-2
164 RNA folds into a stem-loop structure, which may be highly conserved among coronaviruses.
165 This is in contrast to the entire 3' UTR as a whole, for which we do not observe any well-
166 defined global structure.

167

168 **Design of LNA ASO gapmers against the s2m element; assessment of binding and activity** 169 ***in vitro***

170

171 Although the highly conserved nature of the s2m element makes it an attractive target for
172 therapies based on ASOs, the structured nature of the target may potentially interfere with
173 ASO-target base-pairing. To facilitate gapmer-induced disruption of the native s2m structure,
174 we designed gapmers so that the high-affinity LNA bases would pair with the RNA bases
175 predicted to be exposed in the s2m element (Fig. 2 and Table 3). This pairing should facilitate
176 initial gapmer-target interaction, hypothetically leading to unfolding of the s2m element as the
177 rest of the gapmer base-pairs with the complementary target nucleotides.

178

179 We designed a panel of gapmers and tested their ability to direct RNase H cleavage *in vitro*,
180 using s2m RNA as the substrate for the purified enzyme (Fig. 2A and D). Gapmers 1-3 were
181 designed to have higher affinity for target RNA than gapmers 4-6, as indicated by respective
182 predicted melting temperatures (schematic top panel, Fig. 2 and Table 3). The presence of the
183 sequence-specific gapmers 1-6 in the digestion reactions led to clear degradation of target
184 RNA, regardless of their predicted melting temperature bracket, whereas non-sequence-
185 specific control gapmer with scrambled sequence failed to have an effect ("scr", Fig. 2D). The
186 degradation was very efficient even for 2:1 s2m:gapmer molar ratio, indicating that gapmers
187 can be recycled and can direct multiple turnover of substrates by RNase H. Gapmers 1-6 also
188 drove cleavage of the whole 3' UTR (Fig. 2B and E) and of the "extended 3' UTR" construct
189 that additionally includes ORF10 and the region immediately upstream of it (Fig. 2F),
190 indicating that the target s2m sequence is successfully recognised and is accessible for gapmer
191 base-pairing in its native sequence context. The observation that both the higher-affinity
192 gapmers 1-3 (Fig. 2A and B) and the lower-affinity gapmers 4-6 (Fig. 2 D, E and F) were able
193 to direct RNase H cleavage of the s2m element indicates that a range of gapmer-target affinities
194 are compatible with successful target degradation of the highly structured s2m sequence. This
195 flexibility in gapmer design is particularly important as higher affinity gapmers may be
196 expected to have more off-target interactions in cells, which may be reduced in lower-affinity
197 variants.

198

199 Additionally, we designed and tested gapmers targeting a single-stranded conserved region in
200 SARS-CoV-2, at position 1359-1374 relative to the NC_045512.2 virus reference genome
201 (“ss3”; Rangan et al., 2020) and tested alternative gapmer backbone chemistries with these.
202 Gapmers designated “all” and “some” have the same sequence and base composition, but
203 different polymer backbones (Table 3). The entire backbone of gapmer “all” contains
204 phosphorothioate modifications, as is also the case in gapmers 1-6; it is a well-established
205 modification conferring some nuclease resistance to oligonucleotides (Kumar et al., 1998;
206 Eckstein, 2000). The backbone in gapmer “some”, however, is mixed; DNA bases are linked
207 by phosphodiester backbone, whereas LNA bases are linked by phosphorothioate backbone.

208
209 *In vitro* digestion experiments (Fig. 2C) indicate that both chemistries are compatible with
210 RNase H recruitment and target RNA degradation and also suggest general applicability of
211 gapmer-induced degradation of viral RNA sequences. Gapmer “some” appears to have higher
212 binding affinity for the “ss3” target, judging from the presence of an extra band at the top of
213 the gel in Fig. 2C, which likely corresponds to a gapmer-target dimer. This is consistent with
214 expectation, as phosphorothioate modifications are known to reduce target affinity (Grünweller
215 et al., 2003), so gapmer “all” would be expected to show weaker binding than gapmer “some”.
216 On the other hand, gapmer “all” generates a higher amount of cleaved product (Fig. 2C), which
217 supports our choice of phosphorothioate backbone throughout gapmers 1-6.

218

219 **s2m structure is successfully remodelled by LNA gapmers**

220

221 To test whether gapmers have any effect on the s2m structure, we performed SHAPE probing
222 of SARS-CoV-2 3' UTR in the presence of gapmers 1, 2 and 3 targeting s2m and gapmer “all”
223 as a non-specific control. Since SHAPE probing detects the accessibility of nucleotides (Spitale
224 et al., 2013), it is capable of revealing both intra- and inter-molecular RNA base-pairing
225 interactions.

226

227 In the presence of gapmer 1 and gapmer 2, SHAPE reactivity profiles strongly decreased in the
228 regions targeted by the gapmers, indicating inter-molecular interactions formed between
229 gapmers and their target sequences (Fig. 3A-D). In contrast, SHAPE reactivities strongly
230 increased in the regions that were originally base-paired with the gapmer-target regions and in
231 their flanking regions, indicating they were more single-stranded in the presence of gapmers,
232 consistent with expectation.

233

234 In the presence of gapmer 3, which targets the single-stranded loop region within s2m, SHAPE
235 reactivity profile showed a strong decrease in this region (Fig. 3E and F), indicating successful
236 targeting by gapmer. We also found that this inter-molecular interaction between gapmer 3 and
237 the loop region led to increased SHAPE reactivities downstream of the loop region. This
238 suggests that inter-molecular interactions between gapmers and target regions could also
239 remodel the folding status of flanking regions.

240

241 Notably, the observed changes in SHAPE reactivity were dependent on the concentration of
242 gapmers and were not detected in the presence of a control gapmer (gapmer “all”) which is not
243 able to target the s2m element (Fig. 3G and H). Taken together, our results validate the design
244 of gapmers in targeting the s2m element and highlight the effect of gapmers in remodelling
245 s2m structure.

246

247 **s2m acts to direct gapmer-induced reporter gene silencing in human cells**

248

249 To investigate if gapmers against the s2m element could drive target RNA silencing in human
250 cells, we set up a tissue culture-based reporter system. We generated lung-derived A549 and
251 HeLa cell reporter lines carrying stably integrated GFP genes that encode either the wild type
252 s2m element or a scrambled control sequence in the 3' UTR (Fig. S2A and B). Transfection
253 with gapmers against s2m reduced GFP fluorescence levels in the two s2m-containing cell
254 lines for both the higher-affinity gapmers 1-3 and the lower-affinity gapmers 5-6 (Fig. 4A
255 and B). Gapmer 4, the shortest of the tested gapmers and containing only six DNA nucleotides
256 (Table 3), had no effect (Fig. 4A and B); this may reflect difficulties in recruiting human
257 RNase H *in vivo* to this length of RNA-DNA duplex (Kurreck et al., 2002). Non-specific
258 control gapmers did not affect GFP fluorescence levels, nor did treatment with s2m-specific
259 gapmers of control cell lines in which the sequence of the s2m element was scrambled
260 (Fig. S3A and B). These results indicate that the silencing effect relies on sequence-specific
261 gapmer-target interaction. Overall, the results show that gapmers against the s2m element have
262 the potential to silence gene expression from mRNAs containing s2m in their 3' UTR
263 sequences, which is the case for SARS-CoV-2 mRNAs.

264
265 Our experimental method also functioned to test the hypothesis that the s2m is a post-
266 transcriptional response element. We used the GFP reporter cell lines to compare fluorescence
267 levels between the GFP-s2m and GFP-scrambled cells. No difference was observed, indicating
268 that the s2m element itself does not affect fluorescent protein production (Fig. S2C) suggesting
269 that it does not act as an independent element *in cis* in translation of viral mRNAs.

270

271 **LNA gapmers against s2m inhibit replication in an astrovirus replicon model system in** 272 **human cells**

273

274 To investigate the effects of s2m-targeting LNA gapmers on viral replication, initially we
275 employed an astrovirus replicon system. Many (+) ssRNA viruses share a similar repertoire of
276 genetic elements required for the replication of viral RNA, and this is true in the case of
277 coronaviruses and astroviruses. Despite large differences in genome size, coronaviruses and
278 astroviruses possess a similar modular organization, including the order of non-structural and
279 structural genes, a frameshift signal to access the RNA-dependent RNA polymerase (RdRp)
280 open reading frame, and production of 3'-coterminal subgenomic mRNAs for structural and
281 accessory protein expression. Like coronaviruses, many astroviruses – including human
282 astrovirus 1 (HAstV1) – contain an s2m element in the 3' UTR of their genomes (Fig. 5A). We
283 have recently developed a robust HAstV1-based replicon system (Fig. 5A, lower panel), which
284 permits the evaluation of RNA replication in multiple cell types (Lulla and Firth, 2020). The
285 small astroviral genome size (~7 kb) compared to coronaviruses (~30 kb), allows for rapid
286 manipulation of sequences for anti-viral testing in a less restrictive environment than that
287 required to manipulate SARS-CoV-2.

288

289 Building on promising results in a cell-based reporter system, we used the astrovirus system to
290 test gapmer efficacy in the context of virus-like replication, where replicative intermediates are
291 generally physically occluded within host membrane derived vesicles, as is also the case in
292 *bona fide* virus infection. We generated chimeric astrovirus replicons bearing the s2m elements
293 from SARS-CoV or SARS-CoV-2 (Fig. 5B). Chimeric replicons recapitulated the replication
294 properties of the wild-type astrovirus replicon (Fig. 5C), indicating that this system is suitable
295 for testing gapmers against multiple s2m sequences. To rule out any potential cell-specific
296 effects, all gapmers were tested in two human cell lines – Huh7.5.1 (Lulla and Firth, 2020) and
297 HEK293T (optimised for this study). The replication of replicons bearing SARS-CoV-2 s2m
298 sequences was efficiently inhibited by gapmers 1, 2, and 5, causing inhibition in the sub-

299 nanomolar range, with a less pronounced effect found for gapmers 3, 4, and 6. The inhibition
300 of non-specific control gapmers (“all” and “scr”) was significantly below their composition-
301 matched counterparts, gapmers 1-3 and 4-6, respectively (Fig. 5D). The same gapmers were
302 also tested against the SARS-CoV s2m in this system and found to be active, though with a
303 lower potency (Fig. 5E). This could potentially be attributed to differences arising from C-G
304 versus C-U juxtaposition within the respective s2m elements (Fig. 5B), leading to changes in
305 the s2m structure (Aldhumani et al., 2021), thus potentially affecting the s2m gapmer binding
306 properties. Replication in the presence of sufficient concentrations of gapmers 1, 2 or 5
307 dropped to the baseline level of the pO2RL-GNN mutant, which is completely deficient in
308 replication due to a mutated RdRp active site (Fig. 5C).

309
310 To assess the cytotoxicity and potential off-target effects of the tested gapmers, we (i)
311 performed a lactate dehydrogenase release-based cytotoxicity assay, and (ii) evaluated the
312 efficiency of cap-dependent translation in the presence of the different gapmer concentrations.
313 Consistent with previous work (Kaur et al., 2007), these assays showed no gapmer-induced
314 cellular toxicity (Fig. S4A). Translation inhibition of > 50% was only observed at 500 nM
315 concentrations of gapmers 1, 2, 5 and 6 (Fig. S4B), which is at least 10-fold higher than the
316 effective inhibition range for gapmers 1, 2 and 5. Overall, these results suggest that gapmers
317 targeting the s2m element can inhibit viral replication in the model replicon system in a dose-
318 dependent, sequence-specific manner without causing significant cell toxicity.

319 320 **SARS-CoV-2 infection is inhibited by LNA gapmers targeting s2m**

321
322 A high content screening (HCS) assay was developed to measure the effects of LNA gapmers
323 on infection in Vero E6 cells infected with SARS-CoV-2. Figure 6A shows a graphical
324 representation of the HCS assay workflow and an example representative microscopy image,
325 with cells stained for N protein (488 nm signal). We tested gapmers 1-6, “all” and “scr” at 0.25,
326 0.5 and 1 μ M concentrations, a no-gapmer control, and 10 μ M remdesivir treated cells as a
327 positive control. Our results indicate that gapmers 2 and 5 inhibit infection in a dose-dependent
328 manner, reducing virus replication (measured through N protein expression) to 10.4 and 6.9%,
329 respectively, of the non-treated control at 1 μ M concentration, with cell viability at 72% and
330 83%, respectively. Furthermore, the inhibition levels are comparable to the 10 μ M remdesivir
331 control in this assay (Fig. 6B). Gapmer 1, 3, and 6 have a less profound effect (27%, 31%, and
332 17% of non-treated control levels at 1 μ M), whereas gapmer 4 shows the highest toxicity levels
333 besides inhibition to 13% of the non-treated control. In strong agreement with the astrovirus
334 replicon-based results (Fig. 5D), gapmers 2 and 5 demonstrate the most promising results in
335 SARS-CoV-2 inhibition assays (Fig. 6B), suggesting the suitability of these two gapmers for
336 therapeutic development. Consistent with our previous results on other cell lines (Fig. S4A),
337 the gapmers show no cytotoxic effect on Vero E6 cells in the absence of transfection reagent
338 (<5%, Fig. 6C), providing further confidence for potential therapeutic gymnotic delivery (Fazil
339 et al., 2016). These results are consistent with the astrovirus replicon-based approach and
340 indicate that gapmers may have sufficient access to their RNA target in infected cells and that
341 gapmers against the conserved s2m element may act as a viable anti-viral agent, warranting
342 their further exploration as therapeutics.

343 344 **DISCUSSION**

345
346 We have confirmed that the highly conserved structural element s2m in the 3' UTR of SARS-
347 CoV-2 RNA is a site of vulnerability and a feasible candidate for ASO-based targeting by
348 designing LNA-based gapmer ASOs effective against the s2m element *in vitro* and *in vivo*. We

349 demonstrated physical gapmer-induced disruption of the RNA structure, consistent with
350 successful gapmer-target base-pairing interactions, and RNase H-induced target degradation *in*
351 *vitro*. Furthermore, we have demonstrated that the s2m element can direct gapmer-induced
352 silencing of gene expression in GFP reporter assays in human cells, likely relying on the
353 demonstrated enzymatic activity of endogenous RNase H in the nucleus and the cytoplasm
354 (Liang et al., 2017).

355

356 We extended the observation by testing the ability of s2m-targeting gapmers to inhibit viral
357 replication in an astrovirus-based replicon model system, a rapid functional assay that does not
358 require access to higher containment level facilities. Viral replicon assays showed that gapmers
359 against s2m inhibit viral replication in a sequence-specific, dose-dependent manner, down to
360 sub-nanomolar range. These observations confirm that gapmers have significant potential as
361 RNA replication inhibitors. Results from SARS-CoV-2 infection assays in cell culture with
362 LNA gapmers targeting s2m are highly encouraging, with inhibition observed at the 0.25-1 μ M
363 gapmer concentration range. Two of the tested gapmers, 2 and 5, provided consistent inhibition
364 results in both systems without increased cellular toxicity.

365

366 It is worth noting that coronaviruses produce double membrane vesicles inside infected host
367 cells, thought to conceal the viral double-stranded RNA replicative intermediate from cellular
368 defences (Hagemeijer et al., 2012; Knoops et al., 2008). These vesicles have been proposed to
369 be formed through virus-induced manipulations of the membrane of endoplasmic reticulum
370 (Blanchard and Roingard, 2015). This compartmentalization of the SARS-CoV-2 genome in
371 membranous bodies within the host cell's cytoplasm (Klein et al., 2020) may reduce access of
372 the ASOs to the s2m element or other viral genomic targets (although viral mRNAs, which all
373 contain s2m, should still be accessible). In this regard, it is useful to consider that LNA ASOs
374 have been conjugated with tocopherol and cholesterol for membrane association in the past
375 (Benizri et al., 2019; Nishina et al., 2015), which could increase ASO ability to find its target.
376 Improved membrane association may also boost gapmer entry into target cells. The primary
377 targets for the SARS-CoV-2 infection are the ACE2 receptor expressing airway cells, with the
378 virus infection gradually decreasing from the proximal to distal respiratory tract (Hou et al.,
379 2020). These cells might be amenable to aerosol delivery (Drevinek et al., 2020), enabling
380 highly targeted therapeutic administration.

381

382 When considering s2m as a target for virus inhibition, it is also worth noting that while it is a
383 remarkably stable genomic element, conserved across multiple groups of single-stranded
384 (+) sense RNA viruses, some mutations can arise over time. In the SARS-CoV-2 sequences
385 from Covid-19 patient samples, some s2m polymorphisms have been detected at positions 15
386 and 31, predicted to destabilise the stem loop structure (Vahed et al, 2020; Yeh and Contreras,
387 2020). Using a combination of several gapmers together offers a potential strategy to guard
388 against emerging resistance.

389

390 The results described here represent a promising start for further research into targeting
391 conserved elements in single-stranded (+) sense RNA viruses, and support development of
392 gapmers and related ASOs against the s2m element in particular. In the case of the SARS-CoV-
393 2, our gapmer designs offer a strong starting point for further therapeutic development, which
394 may include large scale optimisation and screening to maximise efficacy in cell culture and
395 animal models, as well as chemical modifications for optimal delivery to target cells.

396

397 **ACKNOWLEDGEMENTS**

398

399 AEF and VL are supported by Wellcome Trust (106207) and European Research Council
400 (646891) grants. KJB, TD, KB and BFL are supported by a Wellcome Trust Investigator
401 Award (200873/Z/16/Z) and TD by an Astra-Zeneca Studentship. X.Y and Y.D. are supported
402 by a European Commission Horizon 2020 European Research Council (ERC) Starting Grant
403 (680324). HJM and ND are supported by BBSRC (BBS/E/I/00007031 and BBS/E/I/00007037)
404 grants. All cryoEM grids were prepared and cryoEM data collected at the BIOCEM facility,
405 Department of Biochemistry, University of Cambridge. We thank Dimitri Y. Chirgadze, Steve
406 Hardwick and Lee Cooper for assistance with data collection at the CryoEM Facility. We thank
407 David LV Bauer for critical help with facilitating gapmer tests in virus infection assays. We
408 thank Laura McCoy for the CR3009 antibody expression plasmids and Svend Kjaer at the
409 Structural Biology Service Technology Platform at the Francis Crick Institute for preparation
410 of the antibody. We thank Henrik Oerum, Alex Borodavka, Chris Oubridge and Ulrich
411 Desselberger for invaluable advice and helpful discussions. We thank Dingquan Yu and
412 Zhichao Miao for help with sequence analysis. We thank the support staff in our institutions
413 for their invaluable help throughout the pandemic lockdown period. We dedicate this
414 manuscript to the memory of our colleague Chris Oubridge.

415

416 REFERENCES

417

418 Akula, S. M., & McCubrey, J. A. (2020). Where are we with understanding of COVID-
419 19? *Advances in Biological Regulation*, 77, 100745.

420 <https://doi.org/10.1016/j.jbior.2020.100745>

421

422 Aldhumani, A.H., Hossain, M.I., Fairchild, E. A., Boesger, H., Marino, E.C., Myers, M.,
423 Hines, J.V. (2021). RNA sequence and ligand binding alter conformational profile of SARS-
424 CoV-2 stem loop II motif. *Biochemical and Biophysical Research Communications*, 545, 75-
425 80. <https://doi.org/10.1016/j.bbrc.2021.01.013>

426

427 Benizri, S., Gissot, A., Martin, A., Vialet, B., Grinstaff, M. W., & Barthélémy, P. (2019).
428 Bioconjugated Oligonucleotides: Recent Developments and Therapeutic
429 Applications. *Bioconjugate Chemistry*, 30(2), 366–383.

430 <https://doi.org/10.1021/acs.bioconjchem.8b00761>

431

432 Bennett C. F. (2019). Therapeutic Antisense Oligonucleotides Are Coming of Age. *Annual*
433 *Review of Medicine*, 70, 307–321. <https://doi.org/10.1146/annurev-med-041217-010829>

434

435 Blanchard, E., & Roingeard, P. (2015). Virus-induced double-membrane vesicles. *Cellular*
436 *Microbiology*, 17(1), 45–50. <https://doi.org/10.1111/cmi.12372>

437

438 Bonneau, E., Neveu, B., Kostantin, E., Tsongalis, G. J., & De Guire, V. (2019). How close
439 are miRNAs from clinical practice? A perspective on the diagnostic and therapeutic
440 market. *EJIFCC*, 30(2), 114–127.

441

442 Drevinek, P., Pressler, T., Cipolli, M., De Boeck, K., Schwarz, C., Bouisset, F., Boff, M.,
443 Henig, N., Paquette-Lamontagne, N., Montgomery, S., Perquin, J., Tomkinson, N., den
444 Hollander, W., & Elborn, J. S. (2020). Antisense oligonucleotide eluforsen is safe and
445 improves respiratory symptoms in F508DEL cystic fibrosis. *Journal of Cystic*

446 *Fibrosis*, 19(1), 99–107. <https://doi.org/10.1016/j.jcf.2019.05.014>

447

- 448 Eckstein F. (2000). Phosphorothioate oligodeoxynucleotides: what is their origin and what is
449 unique about them? *Antisense & Nucleic Acid Drug Development*, 10(2), 117–121.
450 <https://doi.org/10.1089/oli.1.2000.10.117>
451
- 452 Fazil, M., Ong, S., Chalasani, M., Low, J.H., Kizhakeyil, A., Mamidi, A., Lim, C.F.H.,
453 Wright, G.D., Lakshminarayanan, R., Kelleher, D., Verma, N.K. (2016). GapmeR cellular
454 internalization by macropinocytosis induces sequence-specific gene silencing in human
455 primary T-cells. *Science Reports*, 6, 37721. <https://doi.org/10.1038/srep37721>
456
- 457 Frey, K. G., Redden, C. L., Bishop-Lilly, K. A., Johnson, R., Hensley, L. E., Raviprakash, K.,
458 Luke, T., Kochel, T., Mokashi, V. P., & Defang, G. N. (2014). Full-genome sequence of
459 human betacoronavirus 2c jordan-n3/2012 after serial passage in Mammalian cells. *Genome*
460 *Announcements*, 2(3), e00324-14. <https://doi.org/10.1128/genomeA.00324-14>
461
- 462 Grünweller, A., Wyszko, E., Bieber, B., Jahnel, R., Erdmann, V. A., & Kurreck, J. (2003).
463 Comparison of different antisense strategies in mammalian cells using locked nucleic acids,
464 2'-O-methyl RNA, phosphorothioates and small interfering RNA. *Nucleic Acids*
465 *Research*, 31(12), 3185–3193. <https://doi.org/10.1093/nar/gkg409>
466
- 467 Hagedorn, P. H., Persson, R., Funder, E. D., Albæk, N., Diemer, S. L., Hansen, D. J., Møller,
468 M. R., Papargyri, N., Christiansen, H., Hansen, B. R., Hansen, H. F., Jensen, M. A., & Koch,
469 T. (2018). Locked nucleic acid: modality, diversity, and drug discovery. *Drug Discovery*
470 *Today*, 23(1), 101–114. <https://doi.org/10.1016/j.drudis.2017.09.018>
471
- 472 Hagemeyer, M. C., Vonk, A. M., Monastyrska, I., Rottier, P. J., & de Haan, C. A. (2012).
473 Visualizing coronavirus RNA synthesis in time by using click chemistry. *Journal of*
474 *Virology*, 86(10), 5808–5816. <https://doi.org/10.1128/JVI.07207-11>
475
- 476 Hou, Y. J., Okuda, K., Edwards, C. E., Martinez, D. R., Asakura, T., Dinnon, K. H., 3rd,
477 Kato, T., Lee, R. E., Yount, B. L., Mascenik, T. M., Chen, G., Olivier, K. N., Ghio, A., Tse,
478 L. V., Leist, S. R., Gralinski, L. E., Schäfer, A., Dang, H., Gilmore, R., Nakano, S., ... Baric,
479 R. S. (2020). SARS-CoV-2 Reverse Genetics Reveals a Variable Infection Gradient in the
480 Respiratory Tract. *Cell*, 182(2), 429–446.e14. <https://doi.org/10.1016/j.cell.2020.05.042>
481
- 482 Huston, N. C., Wan, H., Araujo Tavares, R. C., Wilen, C., & Pyle, A. M. (2020).
483 Comprehensive in-vivo secondary structure of the SARS-CoV-2 genome reveals novel
484 regulatory motifs and mechanisms. *bioRxiv*, 2020.07.10.197079.
485 <https://doi.org/10.1101/2020.07.10.197079>
486
- 487 Jungreis, I., Sealfon, R., & Kellis, M. (2020). Sarbecovirus comparative genomics elucidates
488 gene content of SARS-CoV-2 and functional impact of COVID-19 pandemic
489 mutations. *bioRxiv*, 2020.06.02.130955. <https://doi.org/10.1101/2020.06.02.130955>
490
- 491 Kaur, H., Babu, B. R., & Maiti, S. (2007). Perspectives on chemistry and therapeutic
492 applications of Locked Nucleic Acid (LNA). *Chemical Reviews*, 107(11), 4672–4697.
493 <https://doi.org/10.1021/cr050266u>
494
- 495 Kim, D., Lee, J. Y., Yang, J. S., Kim, J. W., Kim, V. N., & Chang, H. (2020). The
496 Architecture of SARS-CoV-2 Transcriptome. *Cell*, 181(4), 914–921.e10.
497 <https://doi.org/10.1016/j.cell.2020.04.011>


498
499 Klein, S., Cortese, M., Winter, S.L., Wachsmuth-Melm, M., Neufeldt, C.J., Cerikan, B.,
500 Stanifer, M.L., Boulant, S., Bartensclager, R. and Chlanda, P. (2020) SARS-CoV-2 structure
501 and replication characterised by in situ cryo-electron tomography. *bioRxiv*
502 2020.06.23.167064; doi: <https://doi.org/10.1101/2020.06.23.167064>
503
504 Knoops, K., Kikkert, M., Worm, S. H., Zevenhoven-Dobbe, J. C., van der Meer, Y., Koster,
505 A. J., Mommaas, A. M., & Snijder, E. J. (2008). SARS-coronavirus replication is supported
506 by a reticulovesicular network of modified endoplasmic reticulum. *PLoS Biology*, *6*(9), e226.
507 <https://doi.org/10.1371/journal.pbio.0060226>
508
509 Koirala, A., Joo, Y. J., Khatami, A., Chiu, C., & Britton, P. N. (2020). Vaccines for COVID-
510 19: The current state of play. *Paediatric Respiratory Reviews*, S1526-0542(20)30095-6.
511 Advance online publication. <https://doi.org/10.1016/j.prrv.2020.06.010>
512
513 Krammer, F. SARS-CoV-2 vaccines in development. *Nature* **586**, 516-527 (2020).
514 <https://doi.org/10.1038/s41586-020-2798-3>
515
516 Kumar, R., Singh, S. K., Koshkin, A. A., Rajwanshi, V. K., Meldgaard, M., & Wengel, J.
517 (1998). The first analogues of LNA (locked nucleic acids): phosphorothioate-LNA and 2'-
518 thio-LNA. *Bioorganic & Medicinal Chemistry Letters*, *8*(16), 2219–2222.
519 [https://doi.org/10.1016/s0960-894x\(98\)00366-7](https://doi.org/10.1016/s0960-894x(98)00366-7)
520
521 Kurreck, J., Wyszko, E., Gillen, C., & Erdmann, V. A. (2002). Design of antisense
522 oligonucleotides stabilized by locked nucleic acids. *Nucleic Acids Research*, *30*(9), 1911–
523 1918. <https://doi.org/10.1093/nar/30.9.1911>
524
525 Liang, X. H., Sun, H., Nichols, J. G., & Crooke, S. T. (2017). RNase H1-Dependent
526 Antisense Oligonucleotides Are Robustly Active in Directing RNA Cleavage in Both the
527 Cytoplasm and the Nucleus. *Molecular Therapy: the journal of the American Society of Gene*
528 *Therapy*, *25*(9), 2075–2092. <https://doi.org/10.1016/j.ymthe.2017.06.002>
529
530 Low, J. T., & Weeks, K. M. (2010). SHAPE-directed RNA secondary structure
531 prediction. *Methods (San Diego, Calif.)*, *52*(2), 150–158.
532 <https://doi.org/10.1016/j.ymeth.2010.06.007>
533
534 Lulla, V., & Firth, A. E. (2020). A hidden gene in astroviruses encodes a viroporin. *Nature*
535 *communications*, *11*(1), 4070. <https://doi.org/10.1038/s41467-020-17906-x>
536
537 Manfredonia, I., Nithin, C., Ponce-Salvatierra, A., Ghosh, P., Wirecki, T. K., Marinus, T.,
538 Ogando, N. S., Snider, E. J., Martijn J. van Hemert, Janusz M. Bujnicki, Incarnato, D. (2020).
539 Genome-wide mapping of therapeutically-relevant SARS-CoV-2 RNA structures. *bioRxiv*
540 2020.06.15.151647; doi: <https://doi.org/10.1101/2020.06.15.151647>
541
542 Menachery, V. D., Yount, B. L., Jr, Debbink, K., Agnihothram, S., Gralinski, L. E., Plante, J.
543 A., Graham, R. L., Scobey, T., Ge, X. Y., Donaldson, E. F., Randell, S. H., Lanzavecchia, A.,
544 Marasco, W. A., Shi, Z. L., & Baric, R. S. (2015). A SARS-like cluster of circulating bat
545 coronaviruses shows potential for human emergence. *Nature Medicine*, *21*(12), 1508–1513.
546 <https://doi.org/10.1038/nm.3985>
547

- 548 Messner, C. B., Demichev, V., Wendisch, D., Michalick, L., White, M., Freiwald, A.,
549 Textoris-Taube, K., Vernardis, S. I., Egger, A. S., Kreidl, M., Ludwig, D., Kilian, C.,
550 Agostini, F., Zelezniak, A., Thibeault, C., Pfeiffer, M., Hippenstiel, S., Hocke, A., von Kalle,
551 C., Campbell, A., ... Ralser, M. (2020). Ultra-High-Throughput Clinical Proteomics Reveals
552 Classifiers of COVID-19 Infection. *Cell Systems*, *11*(1), 11–24.e4.
553 <https://doi.org/10.1016/j.cels.2020.05.012>
554
- 555 Nishina, T., Numata, J., Nishina, K., Yoshida-Tanaka, K., Nitta, K., Piao, W., Iwata, R., Ito,
556 S., Kuwahara, H., Wada, T., Mizusawa, H., & Yokota, T. (2015). Chimeric Antisense
557 Oligonucleotide Conjugated to α -Tocopherol. *Molecular Therapy. Nucleic acids*, *4*(1), e220.
558 <https://doi.org/10.1038/mtna.2014.72>
559
- 560 Punjani, A., Rubinstein, J. L., Fleet, D. J., & Brubaker, M. A. (2017). cryoSPARC:
561 algorithms for rapid unsupervised cryo-EM structure determination. *Nature Methods*, *14*(3),
562 290–296. <https://doi.org/10.1038/nmeth.4169>
563
- 564 Rangan, R., Zheludev, I. N., Hagey, R. J., Pham, E. A., Wayment-Steele, H. K., Glenn, J. S.,
565 & Das, R. (2020). RNA genome conservation and secondary structure in SARS-CoV-2 and
566 SARS-related viruses: a first look. *RNA (New York, N.Y.)*, *26*(8), 937–959.
567 <https://doi.org/10.1261/rna.076141.120>
568
- 569 Robertson, M. P., Igel, H., Baertsch, R., Haussler, D., Ares, M., Jr, & Scott, W. G. (2005).
570 The structure of a rigorously conserved RNA element within the SARS virus genome. *PLoS*
571 *Biology*, *3*(1), e5. <https://doi.org/10.1371/journal.pbio.0030005>
572
- 573 Singh, S.K., Koshkin, A.A., Wengel, J. and Nielsen, P. (1998) LNA (locked nucleic acids):
574 synthesis and high-affinity nucleic acid recognition. *Chem. Commun.* *4*, 455–456. doi:
575 10.1039/A708608C
576
- 577 Spitale, R. C., Crisalli, P., Flynn, R. A., Torre, E. A., Kool, E. T., & Chang, H. Y. (2013).
578 RNA SHAPE analysis in living cells. *Nature Chemical Biology*, *9*(1), 18–20.
579 <https://doi.org/10.1038/nchembio.1131>
580
- 581 Taiaroa, G., Rawlinson, D., Featherstone, L., Pitt, M., Caly, L., Druce, J., Purcell, D., Harty,
582 L., Tran, T., Roberts, J., Catton, M., Williamson, D., Coin, L., Duchene, S. (2020). Direct
583 RNA sequencing and early evolution of SARS-CoV-2. *bioRxiv* 2020.03.05.976167;
584 doi: <https://doi.org/10.1101/2020.03.05.976167>
585
- 586 Tegunov, D., & Cramer, P. (2019). Real-time cryo-electron microscopy data preprocessing
587 with Warp. *Nature Methods*, *16*(11), 1146–1152. <https://doi.org/10.1038/s41592-019-0580-y>
588
- 589 Tengs, T., & Jonassen, C. M. (2016). Distribution and Evolutionary History of the Mobile
590 Genetic Element s2m in Coronaviruses. *Diseases (Basel, Switzerland)*, *4*(3), 27.
591 <https://doi.org/10.3390/diseases4030027>
592
- 593 Tengs, T., Kristoffersen, A. B., Bachvaroff, T. R., & Jonassen, C. M. (2013). A mobile
594 genetic element with unknown function found in distantly related viruses. *Virology*
595 *Journal*, *10*, 132. <https://doi.org/10.1186/1743-422X-10-132>
596

- 597 Vahed, M., Sweeney, A., Shirazi, F. H., Mirsaedi, M. (2020). Mutation in position of 32
598 (G>U) of S2M differentiate human SARS-CoV2 from Bat Coronavirus. *bioRxiv*
599 2020.09.02.280529; doi: <https://doi.org/10.1101/2020.09.02.280529>
600
- 601 van den Brink, E. N., Ter Meulen, J., Cox, F., Jongeneelen, M. A., Thijsse, A., Throsby, M.,
602 Marissen, W. E., Rood, P. M., Bakker, A. B., Gelderblom, H. R., Martina, B. E., Osterhaus,
603 A. D., Preiser, W., Doerr, H. W., de Kruif, J., & Goudsmit, J. (2005). Molecular and
604 biological characterization of human monoclonal antibodies binding to the spike and
605 nucleocapsid proteins of severe acute respiratory syndrome coronavirus. *Journal of*
606 *Virology*, 79(3), 1635–1644. <https://doi.org/10.1128/JVI.79.3.1635-1644.2005>
607
- 608 Wacker, A., Weigand, J. E., Akabayov, S. R., Altincekic, N., Bains, J. K., Banijamali, E.,
609 Binas, O., Castillo-Martinez, J., Cetiner, E., Ceylan, B., Chiu, L. Y., Davila-Calderon, J.,
610 Dhamotharan, K., Duchardt-Ferner, E., Ferner, J., Frydman, L., Fürtig, B., Gallego, J., Grün,
611 J. T., Hacker, C., ... Zetsche, H. (2020). Secondary structure determination of conserved
612 SARS-CoV-2 RNA elements by NMR spectroscopy. *Nucleic Acids Research*, gkaa1013.
613 Advance online publication. <https://doi.org/10.1093/nar/gkaa1013>
614
- 615 Wahlestedt, C., Salmi, P., Good, L., Kela, J., Johnsson, T., Hökfelt, T., Broberger, C.,
616 Porreca, F., Lai, J., Ren, K., Ossipov, M., Koshkin, A., Jakobsen, N., Skouv, J., Oerum, H.,
617 Jacobsen, M. H., & Wengel, J. (2000). Potent and nontoxic antisense oligonucleotides
618 containing locked nucleic acids. *Proceedings of the National Academy of Sciences of the*
619 *United States of America*, 97(10), 5633–5638. <https://doi.org/10.1073/pnas.97.10.5633>
620
- 621 Yeh, T. Y., & Contreras, G. P. (2020). Emerging viral mutants in Australia suggest RNA
622 recombination event in the SARS-CoV-2 genome. *The Medical journal of Australia*, 213(1),
623 44–44.e1. <https://doi.org/10.5694/mja2.50657>
624
- 625 Zhong, J., Gastaminza, P., Cheng, G., Kapadia, S., Kato, T., Burton, D. R., Wieland, S. F.,
626 Uprichard, S. L., Wakita, T., & Chisari, F. V. (2005). Robust hepatitis C virus infection in
627 vitro. *Proceedings of the National Academy of Sciences of the United States of*
628 *America*, 102(26), 9294–9299. <https://doi.org/10.1073/pnas.0503596102>
629
- 630 Ziv, O., Price, J., Shalamova, L., Kamenova, T., Goodfellow, I., Weber, F., Miska, E. (2020).
631 The short and long-range RNA-RNA interactome of SARS-CoV-2. *Molecular Cell*, 80(6),
632 1067-1077. <https://doi.org/10.1016/j.molcel.2020.11.004>

633 **FIGURES**


634



636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654

Figure 1. s2m is a conserved structural element in the SARS-CoV-2 genome. (A) Sequence alignment of the s2m element in the 3' UTRs of SARS-CoV-2 and SARS-CoV. Lines indicate base-pairing regions within the element. (B) The crystal structure of the SARS-CoV s2m element (adapted from Robertson et al., 2005). (C) Chemical probing of the 3' UTR of SARS-CoV-2. RNA was denatured and refolded in the presence of 100 mM K⁺ and 0.5 mM Mg²⁺, then incubated with NAI (+NAI channel) or DMSO control (-NAI channel). NAI modification was detected by reverse transcription stalling and gel-based analysis. Sequencing lanes were generated by adding ddT (for A), ddG (for C), ddC (for G) and ddA (for U) when performing reverse transcription. The lower panel shows quantification of SHAPE signal in the s2m and flanking regions. Calculation was based on the gel in Fig. 1C, by subtracting the signal of the +NAI lane from that of the -NAI lane. The upper panel shows annotation of SHAPE signal on the s2m structure. The bases with SHAPE signal of 0-0.2, 0.2-0.5, 0.5-0.8 and 0.8-2 were coloured with green, yellow, orange and red, respectively. (D) Representative cryoEM image of the SARS-CoV-2 3' UTR (220 nt) at 2.5 μm defocus. The red arrows indicate features that likely correspond to views along the long axis of duplex regions. The black line in the lower left is a 50 nm scalebar. (E) The 2D class averages and (F) 3D reconstructions as calculated by CryoSparc 2.15.0.

655



656

657

658

659

660

661

662

663

664


665

666

667

Figure 2. Antisense oligomers direct RNase H cleavage of the s2m element and a conserved single stranded region (ss3) in vitro. The upper panel shows the design of the six gapmers that are complementary to the s2m used in this study, as well as a non-specific control gapmer scr (Table 3). The LNA is indicated in orange, phosphorothioate-linked DNA in blue, phosphodiester-linked DNA in light grey. RNase H cleavage of the isolated s2m (A, D), 3' UTR (B, E), the extended 3' UTR (F) and the predicted single-stranded region ss3 (C). Three target to gapmer molar ratios were tested: 1:05, 1:1 and 1:2. Incubation of RNA target with RNase H alone does not lead to cleavage (+RNase H, last lane), and is not driven by control gapmers with scrambled DNA sequence (scr). Incubation of RNA target with gapmer without


668 the addition of RNase H does not lead to degradation either, but does lead to the appearance of
669 a retarded band that likely corresponds to target:gapmer duplex.



670
671

672 **Figure 3. SHAPE probing reveals RNA structure changes induced by LNA gapmers.** (A,
673 C, E, G) SHAPE probing of SARS-CoV-2 3' UTR structure in the presence or absence of the
674 gapmer indicated. RNA was denatured and refolded in the presence of 100 mM K^+ and
675 0.5 mM Mg^{2+} , then incubated with different amounts of gapmer (0 \times , 0.5 \times , 1 \times , 2 \times that of RNA)
676 and probed using NAI. (B, D, F, H) Quantification of A, C, E and G, respectively. Analysis of
677 the differences in SHAPE signal from SARS-CoV-2 3' UTR alone and in the presence of
678 2 \times gapmer. Red arrows indicate the start and end points of gapmer target regions. (A and B)
679 The presence of gapmer 1 induced an increase in SHAPE signal at positions 70-74 and 79-94,
680 highlighted in orange, indicating that these nucleotides are more unstructured. A strong
681 decrease in SHAPE signal was observed at positions 60-69, highlighted in blue, indicating
682 decreased accessibility of these bases, which could be caused by their base-pairing with the
683 gapmer. (C and D) The reactivity profile in D is similar to that in B, due to the similar target
684 regions of gapmer 1 and gapmer 2. (E and F) In the presence of gapmer 3, nucleotides at
685 positions 69-75 are more structured, while nucleotides at positions 76-94 are less structured, as


686 indicated. (G and H) No significant differences in SHAPE signal could be detected in the
687 presence or absence of the non-specific control gapmer “all”, indicating that it is unable to
688 cause structural changes in the SARS-CoV-2 3' UTR.
689



690
691
692
693
694
695

Figure 4. Gapmer-induced reduction of protein levels in cell reporter assays. Flow cytometry analysis of the GFP expressing cells. HeLa (A) and A549 (B) cell lines containing a genomic insertion of a GFP reporter construct with the s2m sequence in its 3' UTR (GFP-s2m) were transfected with 20 nM of the indicated gapmers and analysed 72 h post-transfection


696 by flow cytometry. Treatment with gapmers against the s2m element, but not a nonspecific
697 control gapmer, induced reduction in fluorescence, as detected by flow cytometry. Data are
698 representative of three independent experiments.
699



700
701

Figure 5. Inhibition of astrovirus replicon activity by gapmers targeting the SARS-CoV-2 s2m RNA element. (A) Schematic of the SARS-CoV-2 and human astrovirus 1 (HAstV1) genome organisation. The lower panel represents the astrovirus replicon (pO2RL). FS, frameshift signal; SG, subgenomic; RLuc, Renilla luciferase; RdRp, RNA dependent RNA polymerase. The presented virus and replicon genomes are not to scale. (B) Conservation of the s2m 3' UTR element (two-dimensional representation) between HAstV1, SARS-CoV and SARS-CoV-2. In the astrovirus replicon, the HAstV1 s2m was switched for the SARS-CoV or SARS-CoV-2 s2m; the wild-type and chimeric replicons are indicated below. Gapmers (1, 2, 3 and 4, 5, 6) are colour-coded in light, medium and dark magenta, respectively. (C) Luciferase activity of the wildtype, chimeric, and replication-deficient (RdRp GDD motif mutated to GNN) astrovirus replicons measured in Huh7.5.1 (dark blue bars) and HEK293T (light blue

713 bars) cells. **(D)** Inhibition of the SARS-CoV-2 chimeric replicon by gapmers at 0.5-500 nM
714 concentration range. **(E)** Inhibition of the SARS-CoV chimeric replicon by gapmers at 0.5-
715 500 nM concentration range. For D-E, all data are presented as mean \pm s.d.; $n = 3$ biologically
716 independent experiments, full data and statistical analyses are provided in Supplementary
717 Tables S1 and S2. Replicon activity is presented as the ratio of Renilla (subgenomic reporter)
718 to Firefly (cap-dependent translation, loading control), normalized by the same ratio for the
719 untreated control replicon.
720



721
722

723 **Figure 6. Inhibition of SARS-CoV-2 infection by gapmers targeting the s2m RNA**
 724 **element.** (A) Graphic representation for the high content screening assay experiment
 725 workflow: transfection of Vero E6 cells with gapmers followed by infection with SARS-CoV-
 726 2, fixation of the plate, labelling and screening. A representative image from the
 727 immunofluorescence-based detection of SARS-CoV-2 infection of Vero E6 cells is shown
 728 below. (B) Vero E6 cells were transfected with gapmers 1-6 against the s2m element or control
 729 gapmers “all” and “scr” at 0.25, 0.5, and 1 μM final concentration and infected with SARS-
 730 CoV-2, fixed, labelled and analysed. Results are presented as mean ± s.d.; *n* = 3 biological
 731 replicates; signal normalised to a no-gapmer control. Cell viability was evaluated using the
 732 DRAQ7 signal normalised to mock treated wells. *P*-values are from two-tailed *t*-tests with
 733 separate variances (ns, *p* > 0.05; *, *p* ≤ 0.05; **, *p* ≤ 0.01; ***, *p* ≤ 0.001). (C) Toxicity assay
 734 for gapmer-treated Vero E6 cells in the absence of transfection reagent. Cells were treated with
 735 0.25, 0.5, and 1 μM gapmers for 24 h. Supernatant was used to measure cell viability,
 736 calculated as the ratio of released to total lactate dehydrogenase (LDH)
 737 activity; “max” = maximum LDH measured for fully lysed cells. Full data and statistical
 738 analyses for B-C are provided in Supplementary Tables S3 and S4.
 739

740 MATERIALS AND METHODS

741

742 *RNA preparation*

743 3' UTRs and the s2m 47-mer were prepared by *in vitro* transcription (IVT). Templates for IVT
744 were generated either by PCR, using Phire Hotstart II polymerase (Thermo Fisher) according
745 to manufacturer's instructions, or by hybridising complementary DNA oligonucleotides
746 (Sigma). Sequences for the PCR primers and the DNA oligonucleotides are given in Table 2.
747 RNA generated by IVT was purified: IVT products were separated on polyacrylamide
748 denaturing gel (National Diagnostics), relevant bands were excised using UV shadowing and
749 electroeluted in TBE (Whatman Elutrap), then cleaned up using PureLink™ RNA Microscale
750 Kit (Invitrogen). RNA concentrations were estimated using UV absorbance (A_{260nm}) and a
751 calculated extinction coefficient.

752

753 *Gel-based RNA cleavage assay*

754 Each gapmer was pre-incubated with target RNA in 1× RNase H buffer (Thermo Scientific)
755 for 10 min at 37 °C. 2.5 U of RNase H (Thermo Scientific) was then added and the reaction
756 incubated for 20 min at 37 °C. Reactions were quenched by adding an equal volume of
757 proteinase K mix (0.5 mg/mL enzyme, 100 mM Tris-HCl pH 7.5, 150 mM NaCl,
758 12.5 mM EDTA, 1% w/v SDS) and incubating at 50 °C for 20 min. RNA was visualised on
759 polyacrylamide 7.5 M urea gel (National Diagnostics) in TBE using SybrGold (Invitrogen).

760

761 *Chemical probing of the 3' UTR*

762 To probe RNA structure without gapmers, 5 pmol RNA (~350 ng) was dissolved in 9 µl
763 nuclease-free water, and denatured at 95 °C for 90 s, then cooled on ice for 2 min. RNA was
764 refolded by adding 10 µl of 2× SHAPE probing buffer (80 mM HEPES, pH 7.5, 200 mM KCl,
765 1 mM MgCl₂) and incubating at 37 °C for 15 min. 2-methylnicotinic acid imidazolide (NAI)
766 was added to a final concentration of 100 mM in 20 µl reaction; in control reactions, same
767 volume of DMSO was added instead. Reactions were allowed to proceed at 37 °C for 5 min
768 and then quenched by adding 10 µl of 2 M DTT. RNA was purified by loading quenched
769 samples onto Micro Bio-spin Columns with Bio-Gel P-6 (BioRad), followed by ethanol
770 precipitation. Purified RNA was then dissolved in 6 µl water, reverse-transcribed into cDNA
771 and analysed by PAGE as described below.

772

773 To probe RNA structure with gapmers, different amounts of gapmers were added to refolded
774 RNA, at molar ratios of 0.5×, 1× or 2×, and incubated at 37 °C for 10 min. The same volume
775 of water was added for the no-gapmer control. After co-incubation, RNA was probed using
776 NAI as described above. In addition, un-probed input RNA was also subjected to Sanger
777 sequencing: RNA was dissolved in 5 µl water and supplemented with 1 µl of 10 mM
778 corresponding ddNTP (Roche), then reverse-transcribed into cDNA and analysed by PAGE as
779 described below.

780

781 *Reverse transcription and PAGE analysis of cDNA*

782 6 µl of each RNA-containing sample was mixed with 1 µl of 5 µM Cy5-modified RT primer
783 (sequence given in Table 2) and 0.5 µl of 10 mM dNTPs. The mixture was incubated at 95 °C
784 for 3 min to denature the RNA and then cooled to 50 °C. RT reaction was started by adding
785 2 µl of 5× RT buffer (100 mM Tris pH 8.3, 500 mM LiCl, 15 mM MgCl₂, 5 mM DTT) and
786 0.5 µl Superscript III enzyme (Invitrogen), mixing quickly with a pipette tip. Reaction was
787 allowed to proceed at 50 °C for 20 min, then quenched by incubation at 85 °C for 10 min,
788 which inactivates the enzyme. In order to degrade RNA and liberate the complementary cDNA,

789 the reaction mix was then supplemented with 0.5 μ l of 2 M NaOH and incubated at 95 °C for
790 10 min. The reaction was stopped by adding an equal volume of 2 \times stopping buffer
791 (95% formaldehyde, 20 mM EDTA pH 8.0, 20 mM Tris-HCl pH 7.5, orange G dye) and
792 incubating at 95 °C for 5 min. The resulting cDNA sample was cooled down to 65 °C and
793 analysed on an 8% Acrylamide:Bis-Acrylamide-Urea gel by electrophoresis. The gel was
794 imaged using Typhoon FLA 9000 Gel Imager (GE healthcare).

795

796 ***Quantitative Gel Analysis and SHAPE Reactivity Calculation***

797 Signal intensity of each band on the PAGE gel was detected using ImageQuant TL software
798 and normalized to the total signal of the whole lane. Raw reactivity was generated by
799 subtracting the signal of NAI channel from that of the DMSO control channel; reactivities with
800 negative values were corrected to 0. SHAPE reactivity was generated following the 2/8 %
801 normalization method (Low and Weeks, 2010). To calculate the differences in SHAPE signal
802 in the presence and absence of gapmers, the lanes of NAI channels with 2 \times gapmer (+gapmer)
803 or without gapmer (-gapmer) were used. The signal intensity of each band was normalized to
804 the total signal of the whole lane. Differences were calculated by subtracting the signal of the
805 +gapmer channel from that of the -gapmer channel and then rescaled to the signal of the -
806 gapmer channel.

807

808 ***Cryo electron microscopy***

809 5 μ M purified 3' UTR in 10 mM Tris pH 7.6, 10 mM KCl, 10 mM NaCl was annealed by
810 sequential incubation at 95 °C for 2 min, at 50 °C for 2 min, at 37 °C for 5 min and then at
811 room temperature. The sample was supplemented with 1 mM MgCl₂. 3 μ l of the resultant
812 mixture was applied to glow-discharged (EasiGlow Pelco) R2/2 Quantifoil grids (Quantifoil).
813 Excess sample was blotted away with a FEI Vitrobot (IV) (100% humidity, 4 °C, blotting force
814 0, 3 s blot time) and the grids were vitrified in liquid ethane. The grids were screened with a
815 200 kV FEI Talos Arctica microscope with a Falcon III camera and a data set was collected on
816 a 300 kV FEI Titan Krios microscope equipped with a Gatan K3 camera. Motion correction,
817 ctf estimation and particle-picking were performed in Warp (Tegunov and Cramer, 2019) and
818 2D/3D alignments and averaging were carried out with cryoSPARC 2.15 (Punjani et al., 2017).

819

820 ***Gapmer reporter assays***

821 The s2m sequence or control scrambled sequence of s2m (s2m_scr) was inserted into the
822 3' UTR of GFP in H6P plasmid using In-Fusion Cloning kit (TaKaRa) and verified by
823 sequencing. HEK293ET, HeLa and A459 cells, as well as all stable cell lines, were grown in
824 IMDM medium supplemented with 10% FCS at 37 °C in 5% CO₂. All cell lines tested negative
825 for mycoplasma. Constructs in H6P plasmids were used to produce recombinant lentivirus in
826 HEK293ET cells for the stable expression of GFP reporter in mammalian cells from a
827 constitutive SFFV promoter. HeLa and A549 stable cell lines were generated by lentiviral
828 transduction with low MOI (>0.3) to ensure single genomic integrations and were selected for
829 by drug resistance.

830

831 To examine the effect of gapmers on GFP expression, HeLa or A549 cells with a stably
832 integrated GFP-s2m/s2m_scr reporter were seeded at 5 \times 10⁴ cells per well in 24-well plates.
833 The following day, cells were transfected with gapmer to achieve 20 nM final concentration
834 using Lipofectamine RNAiMAX (Thermo Fisher Scientific). Flow cytometry analysis was
835 performed 72 h after transfection. Cells were washed twice with warm PBS, detached with
836 trypsin and resuspended in IMDM. All samples were analysed on a BD LSR ii flow cytometer,
837 using the high throughput system (HTS), and at least 20,000 events were acquired for each
838 sample. Data were analysed in FlowJo (v10.7.1). Main cell population was identified and gated

839 on Forward and Side Scatter using the Auto Gate tool and plotted as a histogram to visualise
840 GFP intensity of cells (measured using B-525 detector).

841

842 ***Virus replicon assays***

843 HEK293T cells (ATCC) were maintained at 37 °C in DMEM supplemented with 10% fetal
844 bovine serum (FBS), 1 mM L-glutamine, and antibiotics. Huh7.5.1 cells (obtained from Apath,
845 Brooklyn, NY; Zhong et al., 2005) were maintained in the same media supplemented with non-
846 essential amino acids. All cells were mycoplasma tested (MycoAlert™ PLUS Assay, Lonza);
847 Huh7.5.1 cells were also tested by deep sequencing.

848

849 The HAstV1 replicon system is based on the HAstV1 infectious clone, where the virus genome
850 is left intact up to the end of ORFX, then followed by a foot-and-mouth disease virus 2A
851 sequence and a *Renilla* luciferase (RLuc) sequence fused in the ORF2 reading frame, followed
852 by the last 624 nt of the virus genome and a poly-A tail (Fig. 4A, GenBank accession number
853 MN030571; Lulla and Firth, 2020). The s2m mutations were introduced using site-directed
854 mutagenesis and all constructs were confirmed by sequencing. The resulting plasmids were
855 linearized with *XhoI* prior to T7 RNA transcription.

856

857 Huh7.5.1 and HEK293T cells were transfected in triplicate with Lipofectamine 2000 reagent
858 (Invitrogen), using the protocol in which suspended cells are added directly to the RNA
859 complexes in 96-well plates. For each transfection, 100 ng replicon, 10 ng firefly luciferase-
860 encoding purified T7 RNA (RNA Clean and Concentrator, Zymo research), the indicated
861 amount of gapmers, and 0.3 µl Lipofectamine 2000 in 20 µl Opti-Mem (Gibco) supplemented
862 with RNaseOUT (Invitrogen; diluted 1:1,000 in Opti-Mem) were added to each well containing
863 5×10^4 cells in 100 µl DMEM supplemented with 5% FBS, and incubated at 37 °C for 12 h
864 (Huh7.5.1) or 18 h (HEK293T). Firefly and Renilla luciferase activities were determined using
865 the Dual Luciferase Stop & Glo Reporter Assay System (Promega). Replicon activity was
866 calculated as the ratio of Renilla (subgenomic reporter) to Firefly (cap-dependent translation,
867 loading control), normalized by the same ratio for the control replicon, as indicated for each
868 experiment. Three independent experiments, each in triplicate, were performed to confirm
869 reproducibility of results.

870

871 ***Cytotoxicity assays***

872 The analysis of gapmer cellular cytotoxicity in HEK293T, Huh7.5.1, and Vero E6 cells was
873 performed using the CyQUANT LDH cytotoxicity assay (Thermo Scientific). Leaked
874 cytoplasmic enzyme LDH in cell culture supernatants was quantified after enzymatic
875 conversion, and absorbance was measured at 490 nm in a 96-well plate reader according to the
876 manufacturer's instructions.

877

878 ***SARS-CoV-2 production and infection***

879 Vero E6 cells obtained from Oliver Schwarz (Institute Pasteur, Paris) were maintained in
880 DMEM modified with high glucose, L-glutamine, phenol red and sodium pyruvate
881 (ThermoFisher, #41966-029) supplemented with 10% FCS at 5% CO₂. SARS-CoV-2 strain
882 BetaCoV/England/02/2020 (obtained from Public Health England) was propagated at 37°C on
883 Vero E6 cells in DMEM supplemented with 10% FCS at 37 °C. The titer was determined by
884 plaque assay as follows: confluent monolayers of VeroE6 cells were grown on 6-well plates
885 and incubated with 200 µl of a 10-fold serial dilution of virus stock in DMEM supplemented
886 with 10% FCS for 1 h at room temperature. These cells were then overlaid with 0.5× DMEM
887 supplemented with 1% FCS and 1.2% Avicel (BMC Biopolymers, Belgium). After 4 days
888 incubation at 37 °C, cells were fixed with 4% formaldehyde in PBS followed by staining with

889 0.1% toluidine blue (Sigma, #89640). The titer was calculated as plaque forming units (PFU)
890 per ml.

891

892 **SARS-CoV-2 infection assay**

893 Vero E6 cells (NIBC, UK) were grown in DMEM (containing 10 % FBS) at 37 °C and 5 %
894 CO₂ in 96 well imaging plates (Greiner 655090). Cells were transfected with individual
895 gapmers at 0.25, 0.5 or 1 μM final concentration using Lipofectamine 2000 (Thermo Fisher),
896 according to manufacturer's instructions. At 6 h post transfection, the media was replaced and
897 the cells were infected or mock infected with SARS-CoV-2 at a multiplicity of infection
898 0.5 PFU/cell. At 22 h post-infection, cells were fixed, permeabilised and stained for SARS-
899 CoV-2 N protein using Alexa488-labelled-CR3009 antibody (van den Brink et al., 2005) and
900 for nuclei (DRAQ7, 647 nm wavelength). The plate was imaged using the high content
901 screening microscope Opera Phenix from Perkin Elmer with a 5× lens. The Opera Phenix-
902 associated software Harmony was used to delineate the whole well area and to determine the
903 total intensities of the Alexa488/N protein and DRAQ7/DNA signals per said whole well area
904 during image acquisition. The background subtracted Alexa488/N intensities were normalised
905 to vehicle treated samples. Toxicity was evaluated using the DRAQ7/DNA signal normalised
906 to mock treated wells and LDH release-based cytotoxicity assay.

907

908 **TABLES**

909

910 **Table 1. Sequence of the RNA used in this study**

911

912 The sequence in bold corresponds to the extended s2m region common for these RNA
913 substrates.

914

SARS-CoV-2 s2m sequence used in RNase H assays <i>in vitro</i> and in GFP reporter assays (47 nt)
GGAGUUCACCGAGGCCACGCGGAGUACGAUCGAGUGUACAGUGAAUU
Scrambled control sequence used in GFP reporter assays (47 nt)
AGCCGGGCUGGAAGAUACUGCCCCAAAUAGGGAACUUUGACGCGGUUG
SARS-CoV-2 3' UTR (220 nt)
UAGCAAUCUUUAAUCAGUGUGUAACAUAUAGGGAGGACUUGAAAGAGCCACCACAUUUUCAC CGAGGCCACGCGGAGUACGAUCGAGUGUACAGUGAACA AUGCUAGGGAGAGCUGCCUAUA UGGAAGAGCCUAAUGUGUAAAAUUAUUUUAGUAGUGCUAUCCCCAUGUGAUUUUAAUAG CUUCUUAGGAGAAUGACAAAAAAAAAAAAAAAAAAAAA
SARS-CoV-2 extended 3' UTR (358 nt)
ACUCAUGCAGACCACACAAGGCAGAUGGGCUAUUAACGUUUUCGCUUUUCCGUUUACGAU AUUAUGUCUACUCUUGUGCAGAAUGAAUUCUCGUAACUACAUAGCACAAGUAGAUGUAGUU AACUUUAAUCUCACAUAGCAAUCUUUAAUCAGUGUGUAACAUAUAGGGAGGACUUGAAAGAG CCACCACAUUUUCACCGAGGCCACGCGGAGUACGAUCGAGUGUACAGUGAACAUGCUAG GGAGAGCUGCCUAUAUGGAAGAGCCUAAUGUGUAAAAUUAUUUUAGUAGUGCUAUCCCC AUGUGAUUUUAAUAGCUUCUUAGGAGAAUGACAAAAAAAAAAAAAAAAAAAAA
SARS-CoV-2 ss3 (16 nt). A conserved region predicted to be single-stranded in the genome; positions 1359-1374 relative to the NC_045512.2 reference (Rangan et al., 2020)
UUGUAAAAUUUAUUG

915

916

917 **Table 2. Primers for IVT and SHAPE analysis**

918

Name	Type	Sequence
3' UTR_F	IVT primer	GTTTTTTAATACGACTCACTATAGCAATCTTTAATCAGTGTG TAACATTAGG
Extended 3' UTR_F	IVT primer	GTTTTTTAATACGACTCACTATTACTCATGCAGACCACACA AGGC
3' UTR_R	IVT primer	TTTTTTTTTTTTTTTTTTTTTTTGTTCATTCTCCTAAGAAGC
S2M_F	IVT primer	GTTTTTTAATACGACTCACTATAGGAGTTCACCGAGGCCAC GCGGAGTACGATCGAGTGTACAGTGAATT
S2M_R	IVT primer	AATTCACTGTACACTCGATCGTACTCCGCGTGGCCTCGGTG AACTCCTATAGTGAGTCGTATTAATAAAC
COV19_RT1	SHAPE Primer	Cy5-TTTTGTTCATTCTCCTAAGAAGCT
COV19_RT2	SHAPE Primer	Cy5-CTCTTCCATATAGGCAGCTC

919

920

921 **Table 3 Gapmers used in this study**

922

923 Notation: * = phosphorothioate backbone linkage; [+X] = LNA base X.

924 Melting temperature predictions were obtained using an online oligo design tool

925 (<https://www.qiagen.com/>).

926


Name	Sequence	DNA T _m (°C)	RNA T _m (°C)
Gapmer 1	[+A]*[+C]*[+T]*[+C]*C*G*C*G*T*G*G*C*[+C]*[+T]*[+C]*[+G]	85	93
Gapmer 2	[+T]*[+A]*[+C]*[+T]*C*C*G*C*G*T*G*G*[+C]*[+C]*[+T]*[+C]	81	97
Gapmer 3	[+G]*[+A]*[+T]*[+C]*G*T*A*C*T*C*C*G*[+C]*[+G]*[+T]*[+G]	78	88
Gapmer 4	[+G]*[+C]*G*T*G*G*C*C*[+T]*[+C]*[+G]	69	76
Gapmer 5	[+G]*[+A]*T*C*G*T*A*C*T*C*C*G*C*[+G]*[+T]*[+G]	70	76
Gapmer 6	[+T]*[+T]*[+C]*A*C*T*G*T*A*C*A*C*T*[+C]*[+G]*[+A]	68	79
scr	[+A]*[+C]*C*G*T*G*C*G*G*T*A*T*T*[+C]*[+G]*[+C]	71	75
all	[+C]*[+A]*[+A]*[+T]*A*A*A*T*T*T*A*[+A]*[+C]*[+A]*[+A]	53	50
some	[+C]*[+A]*[+A]*[+T]AAATTTTA[+A]*[+C]*[+A]*[+A]	53	50

927

928

929 SUPPLEMENTARY FIGURES

930



931


932

933 **Figure S1**, related to Figure 1. **SHAPE analysis of the extended 3' UTR of SARS-CoV-2**

934 (A) Chemical probing of the extended 3' UTR of SARS-CoV-2 (including ORF10 and the
935 region immediately upstream of it). RNA was denatured and refolded in the presence of
936 100 mM K⁺ and 0.5 mM Mg²⁺, then incubated with NAI (+NAI channel) or DMSO control (-
937 NAI channel). NAI modification was detected by reverse transcription stalling and gel-based
938 analysis. Sequencing lanes were generated by adding ddT (for A), ddG (for C), ddC (for G)
939 and ddA (for U) when performing reverse transcription. (B) Quantification of SHAPE signal
940 on at the s2m element and flanking regions. Calculation was based on the gel in Fig. S1A, by
941 subtracting the signal of the +NAI lane from that of the -NAI lane. (C) Agreement of SHAPE
942 signal on s2m structure in the 3' UTR and the extended 3' UTR of SARS-CoV-2. Pearson
943 correlation coefficient was calculated based on the SHAPE signals shown in Fig. 1C and
944 Fig. S1B.


945

A




946

B



C



947

948

949

950

951


952

953

954

Figure S2, related to Figure 4. s2m element does not influence RNA translation in the reporter assay in human cells. (A) Schematic of the GFP reporter assay. (B) Gating and data visualisation strategy of the reporter assay data. Main cell population was identified and gated on Forward and Side Scatter using the Auto Gate tool and plotted as a histogram to visualise GFP intensity of cells. (C) HeLa and A549 cell lines containing a genomic insertion of a GFP reporter construct without additional insertion in its 3' UTR (GFP), with the s2m sequence in


955 its 3' UTR (GFP-s2m) or with a scrambled sequence insertion in its 3' UTR (GFP-s2m_scr)
956 were analysed by flow cytometry. Data are representative of two independent experiments.



957
958

959 **Figure S3, related to Figure 4. Gapmer silencing effect relies of sequence-specific gapmer-**
960 **target interaction.** HeLa (A) and A549 (B) cell lines containing a control genomic insertion
961 of a GFP reporter construct with a scrambled sequence inserted in its 3' UTR (GFP-s2m_scr)
962 were transfected with 20 nM of the indicated gapmers and analysed 72 h post-transfection by
963 flow cytometry. The control cell lines containing GFP reporter with a scrambled sequence
964 insertion in the 3' UTR show no appreciable change in fluorescence upon treatment with the
965 gapmers targeted against the s2m element. Data are representative of three independent
966 experiments.

967



968
969

970 **Figure S4, related to Figure 5. Testing the cytotoxic and off-target effects of gapmers. (A)**
971 Toxicity assay for gapmer-treated cells. Cells were treated with 0.5-500 nM gapmers for 24 h.
972 Supernatant was used to measure cell viability, calculated as the ratio of released to total lactate
973 dehydrogenase (LDH) activity; “max” = maximum LDH measured for fully lysed cells. **(B)**
974 The effect on translation measured as a readout of capped T7 RNA encoding firefly luciferase
975 at 0.5-500 nM gapmer concentration, normalized to untreated cells. All data are presented as
976 mean \pm s.d.; $n = 3$ biologically independent experiments.